Last reviewed · How we verify
Autologous UCB Reinfusion
Autologous umbilical cord blood (UCB) cells are reinfused into patients to promote immune reconstitution and tissue repair.
Autologous umbilical cord blood (UCB) cells are reinfused into patients to promote immune reconstitution and tissue repair. Used for Cerebral palsy (Phase 2), Autism spectrum disorder (Phase 2).
At a glance
| Generic name | Autologous UCB Reinfusion |
|---|---|
| Sponsor | Joanne Kurtzberg, MD |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Immunology, Regenerative Medicine |
| Phase | Phase 2 |
Mechanism of action
This therapy involves collecting a patient's own umbilical cord blood stem cells (typically stored at birth) and reinfusing them to support hematopoietic and immunological recovery. The mechanism leverages the regenerative and immunomodulatory properties of cord blood-derived cells, including hematopoietic stem cells and other progenitors, to enhance immune function and potentially repair damaged tissues.
Approved indications
- Cerebral palsy (Phase 2)
- Autism spectrum disorder (Phase 2)
Common side effects
- Infusion-related reactions
- Fever
- Infection
Key clinical trials
- A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous UCB Reinfusion CI brief — competitive landscape report
- Autologous UCB Reinfusion updates RSS · CI watch RSS
- Joanne Kurtzberg, MD portfolio CI